Biofil Chemicals and Pharmaceuticals Ltd (BIOF)

NSE


	Symbol		Exchange		Currency
	BIOF		NSE		INR	Real-time
	BIOF		BSE		INR	Delayed

Currency in INR

65.82

+0.55(+0.84%)

Closed05/12

Fair Value

Day's Range

65.36

66.50

52 wk Range

50.75

91.87

BIOF Income Statement

Featured here, the Income Statement (earnings report) for Biofil Chemicals and Pharmaceuticals Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2015

31/03

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

Total Revenues

297.67

358.1

223.82

300.35

404.09

Total Revenues Growth

+28.49%

+20.3%

-37.5%

+34.19%

+34.54%

Cost Of Revenues

253.68

324.83

195.16

274.72

376.61

Gross Profit

43.99

33.27

28.66

25.63

27.48

Gross Profit Growth

+42.87%

-24.37%

-13.86%

-10.57%

+7.2%

Gross Profit Margin %

14.78%

9.29%

12.8%

8.53%

6.8%

Other Operating Expenses, Total

28.34

13.64

18.32

17.29

18.47

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+21.02%	-51.87%	+34.26%	-5.59%	+6.84%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	8.73	7.59	7.94	6.34	6.82
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	15.53	1.94	6.1	6.66	7.66

Operating Income

15.65

19.63

10.34

8.34

9

Operating Income Growth

+112.28%

+25.43%

-47.3%

-19.37%

+7.94%

EBIT Margin %

5.26%

5.48%

4.62%

2.78%

2.23%

Net Interest Expenses

-1

-0.43

-0.18

-0.4

-0.33

Net Interest Expenses Growth

+28.15%

+57.11%

+57.94%

-123.89%

+18.61%

Interest Expense, Total

-1.21

-0.64

-0.39

-0.42

-0.4

Interest And Investment Income

0.22

0.21

0.21

0.02

0.07

Other Non Operating Expenses, Total

-0.01

-0.04

-0.02

-0.01

-0.02

EBT, Excl. Unusual Items

14.64

19.16

10.15

7.93

8.65

Gain (Loss) On Sale Of Assets

-

0.03

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

14.64

19.19

10.15

7.93

8.65

EBT, Incl. Unusual Items Growth

+144.71%

+31.07%

-47.11%

-21.86%

+9.12%

EBT, Incl. Unusual Items Margin

4.92%

5.36%

4.53%

2.64%

2.14%

Income Tax Expense

2.57

6.78

3.17

2.33

1.56

Net Income to Company

12.07

12.41

6.98

5.6

7.09

Minority Interest

-

-

-

-

-

Net Income

12.07

12.41

6.98

5.6

7.09

Net Income Growth

+150.3%

+2.83%

-43.74%

-19.76%

+26.55%

Net Income Margin %

4.06%

3.47%

3.12%

1.87%

1.76%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

12.07

12.41

6.98

5.6

7.09

Basic EPS - Continuing Operations

0.74

0.76

0.43

0.34

0.44

Basic EPS - Continuing Operations Growth

+150.3%

+2.83%

-43.74%

-19.76%

+26.55%

Diluted EPS - Continuing Operations

0.74

0.76

0.43

0.34

0.44

Diluted EPS - Continuing Operations Growth

+149.69%

+3.08%

-43.74%

-20.77%

+28.17%

Basic Weighted Average Shares Outstanding

16.27

16.27

16.27

16.27

16.27

Diluted Weighted Average Shares Outstanding

16.27

16.27

16.27

16.27

16.27

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

19.73

23.75

14.62

12.63

13

EBITDA Growth

+79.01%

+20.35%

-38.44%

-13.6%

+2.89%

EBITDA Margin %

6.63%

6.63%

6.53%

4.21%

3.22%

EBIT